30 36

Cited 0 times in

Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment.

 Yongsik Jung  ;  Soo Jung Lee  ;  Juneyoung Lee  ;  Woo Chul Noh  ;  Seok Jin Nam  ;  Byeong-Woo Park  ;  Young Tae Bae  ;  Sung-Soo Kang  ;  Heung Kyu Park  ;  Jung-Han Yoon  ;  Je Ryong Kim  ;  Se Hun Cho  ;  Lee Su Kim  ;  Byung In Moon  ;  Sung Hoo Jung  ;  Chol Wan Lim  ;  Sung Yong Kim  ;  Ho Yong Park  ;  Jeongyoon Song  ;  Kwang Man Lee  ;  Sung Hwan Park  ;  Joon Jeong  ;  Hae Lin Park  ;  Sung Won Kim  ;  Beom Seok Kwak  ;  Sun Hee Kang  ;  Young Up Cho  ;  Geum Hee Gwak  ;  Yong Lae Park  ;  Sang Wook Kim  ;  Sehwan Han 
 Journal of Breast Cancer, Vol.21(2) : 182-189, 2018 
Journal Title
 Journal of Breast Cancer 
Issue Date
Breast neoplasms ; Letrozole ; Quality of life ; Treatment
Purpose: There are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer. Methods: Self-reported quality of life (QoL) scores were serially assessed for 3 years during adjuvant letrozole treatment using the Korean version of the Functional Assessment of Cancer Therapy-Breast questionnaires (version 3). Changes in bone mineral density (BMD) and serum cholesterol levels were also examined. Results: All 897 patients received the documented informed consent form and completed a baseline questionnaire before treatment. Adjuvant chemotherapy was administered to 684 (76.3%) subjects, and 410 (45.7%) and 396 (44.1%) patients had stage I and II breast cancer, respectively. Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, and 36 months after enrollment. Of 897 patients, 749 (83.5%) completed the study. The dropout rate was 16.5%. The serial trial outcome index, the sum of the physical and functional well-being subscales, increased gradually and significantly from baseline during letrozole treatment (p<0.001). The mean serum cholesterol level increased significantly from 199 to 205 after 36 months (p=0.042). The mean BMD significantly decreased from -0.39 at baseline to -0.87 after 36 months (p<0.001). Conclusion: QoL gradually improved during letrozole treatment. BMD and serum cholesterol level changes were similar to those in Western countries, indicating that adjuvant letrozole treatment is well tolerated in Korean women, with minimal ethnic variation.
Files in This Item:
T201803971.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
박병우(Park, Byeong Woo) ORCID logo https://orcid.org/0000-0003-1353-2607
정준(Jeong, Joon) ORCID logo https://orcid.org/0000-0003-0397-0005
조영업(Cho, Young Up) ORCID logo https://orcid.org/0000-0003-2936-410X
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.